Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials

Abstract

Much of the information collected in unsuccessful drug trials is inaccessible to the broader research and practice communities. These findings provide an evidence base and rationale for policy reforms aimed at promoting transparency, ethics, and accountability in clinical research.